Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kai-Xin-San
- Development stage
- Unknown
- Lead developer
- Gansu University of Chinese Medicine
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Oral
01
Overview
Kai-Xin-San (KXS) is a classical traditional Chinese medicine (TCM) prescription first recorded in the 7th century in the ancient text *Beiji Qianjin Yaofang* by Sun Simiao. It is composed of four herbal ingredients: Polygalae Radix (root of Polygala tenuifolia), Ginseng Radix et Rhizoma (root and rhizome of Panax ginseng), Poria (sclerotium of Poria cocos), and Acori Tatarinowii Rhizoma (rhizome of Acorus tatarinowii). The typical ratio is 3:3:2:2. Originally used for amnesia, it has been widely applied to treat depression, cognitive decline, and emotional disorders[1][4][6]. Its pharmacological activities include antidepressant effects—demonstrated in animal models resistant to fluoxetine—and neuroprotective actions through modulation of inflammatory cytokines and upregulation of neurotrophic factors such as BDNF via pCREB signaling pathways[3][4]. The main active constituents are saponins, xanthones, oligosaccharide esters, triterpenoids, volatile oils, and flavonoids; saponins are considered predominant for mental health benefits[1][2]. Mechanistically, KXS appears to regulate neurotransmitter levels and neurotrophic factors in the brain as well as modulate gut microbiota composition[1][6].
- Other names
- KaixinsanKXS
02
Targets
AcetylcholinesteraseADRA2A (α2A)CDK5 (Cyclin-dependent kinase 5)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DRD2 (Dopamine D2 Receptor)GSK3 (Glycogen synthase kinase 3 beta)MAOA (Monoamine oxidase A)CHRM2 (M2)NTRK2 (Tropomyosin-related kinase receptor type B)CREB (Cyclic AMP response element-binding protein)
Beyond the preview
Go deeper on Kai-Xin-San.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kai-Xin-San.